Results: In 36 patients who preceded to surgery R0 resection rates were 83% (5 of 6), 71% (5 of 7), and 60% (14 of 23) for resectable, borderline resectable, and unresectable disease, respectively (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Introduction: We evaluated the diagnostic accuracy of computed tomography (CT) in determining resectability of pancre- atic adenocarcinoma using National Comprehensive Cancer Network (NCCN) Criteria.
📊
Key Findings & Data:Methods: Two radiologists retrospectively reviewed abdominal CT images from 36 patients with non-metastatic pancreatic adenocarcinoma who were operated on between 2018 and 20120.
💡
Conclusion & Impact:Results: In 36 patients who preceded to surgery R0 resection rates were 83% (5 of 6), 71% (5 of 7), and 60% (14 of 23) for resectable, borderline resectable, and unresectable disease, respectively (p
🔬Design:Review & Systematic Survey
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters
Abstract
Introduction: We evaluated the diagnostic accuracy of computed tomography (CT) in determining resectability of pancre- atic adenocarcinoma using National Comprehensive Cancer Network (NCCN) Criteria. Methods: Two radiologists retrospectively reviewed abdominal CT images from 36 patients with non-metastatic pancreatic adenocarcinoma who were operated on between 2018 and 20120. Based on CT findings six patients were reported as resectable, seven patients as borderline resectable, and 23 patients as unresectable using NCCN criteria for resectability. Positive predictive values for negative resection margin (R0) were assessed for CT using post-operative histopathological reports as reference standards. Results: In 36 patients who preceded to surgery R0 resection rates were 83% (5 of 6), 71% (5 of 7), and 60% (14 of 23) for resectable, borderline resectable, and unresectable disease, respectively (p
🔖
Cite This Article
SUBAŞI, İ. E., SOYDAN, L., TORUN, M., DEVECİ, C. K., ÖNER, T., CANPOLAT, K., KINA, U. (2022). Computed Tomography Prediction of Resectability of Pancreatic Adenocarcinoma Using National Comprehensive Cancer Network Criteria. Haydarpaşa Numune Medical Journal, Cilt: 61 - Sayı: 2, 189–196. https://ajindex.com/articles/535934
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of inci- dence and mortality worldwide for 36 cancers in 185 coun- tries. CA Cancer J Clin 2018;68:394–424
Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pan- creatic cancer. Ann Surg 2007;246:173–80
Gnerlich JL, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Car- penter DH, et al. Microscopic margins and patterns of treat- ment failure in resected pancreatic adenocarcinoma. Arch Surg 2012;147:753–60
Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor deter- mining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–94
Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: Better prediction of outcome. Ann Surg 2011;254:311–9
Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC can- cer staging manual: Pancreas and hepatobiliary cancers. Ann Surg Oncol 2018;25:845–7
Pathologists TRCo. Standards and datasets for reporting can- cers. In: Dataset for Histo-Pathological Reporting of Carcino- mas of the Pancreas, Ampulla of Vater and Common Bile Duct. 2nd ed. London, England: The Royal College of Pathologists; 2017
Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, et al. Extended pancreatectomy in pancreatic duc- tal adenocarcinoma: Definition and consensus of the inter- national study group for pancreatic surgery (ISGPS). Surgery 2014;156:1–14
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with folfirinox in combination with losartan followed by chemoradiotherapy for locally ad- vanced pancreatic cancer: A phase 2 clinical trial. JAMA Oncol 2019;5:1020–7
Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 2015;33:1770–8